13 patents currently held

4 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Sep 2027. from the record

Of the 4 now held by other companies, 4 name Seismic Pharmaceuticals Operations LLC as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Sep 2027

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

2026202720282029 203020312032 2033 203420352036203720382039204020412042204320442045

notable patents all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Ventilation Circuit Adaptor and Proximal Aerosol Delivery System US 9,592,361

Cited by 18 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.

Ends Sep 2033 · High confidence Also notable

Thienopyrimidine Inhibitors of Atypical Protein Kinase C US 10,183,950

Cited by 13 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.

Ends Nov 2032 · High confidence Also notable

Pulmonary Surfactant Formulations and Methods for Promoting Mucus Clearance US 8,221,772

The largest patent family in this portfolio, 9 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2027.

Ends Sep 2027 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Mar 17, 2027
The maintenance fee for Azaquinazoline Inhibitors Of Atypical Protein Kinase C (US 10,414,763) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 4 largest of its 5 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Pulmonary Surfactant Formulations and Methods for Promoting Mucus Clearance	4 in force	to Mar 2033
Ventilation Circuit Adaptor and Proximal Aerosol Delivery System	3 in force	to Sep 2033
Thienopyrimidine Inhibitors of Atypical Protein Kinase C	3 in force	to Dec 2032
Azaquinazoline Inhibitors of Atypical Protein Kinase C	2 in force	to Feb 2034

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 8,221,772	Pulmonary Surfactant Formulations and Methods for Promoting Mucus Clearance In force Term ends Sep 19, 2027 · High confidence	In force	Term ends Sep 19, 2027	High confidence
US 8,701,658	Ventilation Circuit Adaptor and Proximal Aerosol Delivery System In force Term ends Mar 17, 2029 · High confidence	In force	Term ends Mar 17, 2029	High confidence
US 9,352,114	Ventilation Circuit Adaptor and Proximal Aerosol Delivery System In force Ends no later than Jan 5, 2030 · Medium confidence	In force	Ends no later than Jan 5, 2030	Medium confidence
US 10,183,950	Thienopyrimidine Inhibitors of Atypical Protein Kinase C In force Term ends Nov 19, 2032 · High confidence	In force	Term ends Nov 19, 2032	High confidence
US 10,954,251	Thienopyrimidine Inhibitors of Atypical Protein Kinase C In force Term ends Nov 19, 2032 · High confidence	In force	Term ends Nov 19, 2032	High confidence
US 9,604,994	Thienopyrimidine Inhibitors of Atypical Protein Kinase C In force Term ends Dec 10, 2032 · High confidence	In force	Term ends Dec 10, 2032	High confidence
US 8,748,396	Lyophilization of Synthetic Liposomal Pulmonary Surfactant In force Term ends Mar 28, 2033 · Medium confidence	In force	Term ends Mar 28, 2033	Medium confidence
US 8,748,397	Lyophilization of Synthetic Liposomal Pulmonary Surfactant In force Term ends Mar 28, 2033 · Medium confidence	In force	Term ends Mar 28, 2033	Medium confidence
US 9,554,999	Lyophilization of Synthetic Liposomal Pulmonary Surfactant In force Term ends Mar 28, 2033 · High confidence	In force	Term ends Mar 28, 2033	High confidence
US 9,592,361	Ventilation Circuit Adaptor and Proximal Aerosol Delivery System In force Term ends Sep 9, 2033 · High confidence	In force	Term ends Sep 9, 2033	High confidence

10 of 13 patents shown.

Pro members see all 13.

Pro members: see all 13 patents

Also on record, not counted in the 13: 4 patents in force now held by others · 3 patents ended · 3 applications pending · 1 application abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Windtree Therapeutics, Inc.